https://www.cnn.com/2022/09/27/health/alzheimers-trial-lecanemab/index.html
A monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
Create an account
or login to join the discussion